SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as the community keenly anticipates 48-week IMPACT Phase 2b trial data for its MASH treatment, Pemvidutide, following reports of improved antifibrotic activity and favorable tolerability. Excitement is high around the FDA's support for advancing to a Phase 3 trial and the integration of AI-assisted pathology reads, driving intense speculation about potential strategic partnerships or acquisitions.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending lower following its recent financial results, which highlighted weak demand in the crucial China market and concerns over gross margin compression. Community discussion centers on whether the brand is losing appeal to younger consumers amidst rising competition and questions around management's strategy, with some viewing the dip as a buying opportunity while others express long-term skepticism.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending amid an escalating legal battle, with the company filing a lawsuit alleging stock manipulation by certain investment funds. This high-stakes action has fueled intense community debate, as investors grapple with GRRR's continued stock decline despite recent positive business developments, including substantial contracts and an expanded share buyback program. Many believe the stock is deeply undervalued and is being suppressed by targeted short activity and external pressures unrelated to its core AI and infrastructure business.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata (INOD) is gaining significant attention as investors keenly anticipate a transformative strategic partnership, potentially with a major government or military contractor, expected to be announced before year-end. While bulls are confident in a substantial rally from current oversold conditions, citing INOD's strong fundamentals in the booming AI data training sector, skeptics voice concerns over past delays and the stock's ability to overcome broader market headwinds and institutional buying limitations.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as new developments in its autonomous driving technology, including an in-house AI chip and expanded hands-free driving capabilities, are re-energizing investor conversation. The community is actively discussing how these advancements, alongside the anticipated R2 vehicle, position Rivian as a significant player evolving beyond a traditional EV manufacturer, fueling expectations of substantial growth.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is capturing market attention following bullish analyst upgrades and the confirmation of Jared Isaacman as NASA Administrator, aligning with a new White House executive order for American space superiority. The community is highly anticipating the imminent, multi-billion-dollar Lunar Terrain Vehicle (LTV) contract award, believing LUNR is a leading contender due to its proven lunar mission success. This confluence of catalysts, coupled with heavy short interest, suggests continued volatility and strong upside potential.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is actively discussed following the executive order to reclassify cannabis to Schedule III, a significant policy shift that the company is leveraging to advance its U.S. medical cannabis operations through its newly formed Tilray Medical USA unit. Despite sector-wide volatility interpreted by some as a "sell the news" event, many in the community emphasize the long-term benefits for profitability and institutional investment stemming from this historic regulatory change.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is experiencing significant volatility driven by an upcoming shareholder vote on increasing authorized shares, fueling concerns about potential dilution, and a major investor's planned divestment. Despite its unique NRC-certified SMR technology being touted as crucial for AI's immense energy demands, community sentiment remains sharply divided between those labeling it a "scam" due to recent declines and others seeing a "generational buying opportunity" in the long-term nuclear power narrative.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is actively trending following a stronger-than-expected fiscal Q4 earnings report, driven by increasing optimism around its potential to capitalize on significant data center energy opportunities. The community is buzzing with speculation about FCEL becoming a prominent "AI energy play," highlighting its natural gas-fueled solutions as a timely answer to powering the surging demands of digital infrastructure. While some investors express long-term profit skepticism, the narrative of improving technology and substantial market potential is driving active discussion and interest.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending following stronger-than-expected financial results, driven by ongoing cost-cutting and network transformation initiatives. The community is actively debating the significance of the earnings beat and raised outlook, with bulls anticipating further upside, while others express caution regarding potential impacts from expiring trade exemptions and fierce industry competition. The immediate market reaction has been a key talking point, with some noting limited sustained gains despite the positive report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics, Inc. $CADL is Acorn Capital Advisors LLC's 5th Largest Position

Acorn Capital Advisors LLC boosted its position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 19.9% in the second quarter, according to the company in its most recent Form 13F filing...

Brookline Capital Management Weighs in on CADL Q4 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Stock analysts at Brookline Capital Management issued their Q4 2025 earnings estimates for Candel Therapeutics in a report issued on Sunday...

Stephens Reaffirms Overweight Rating for Candel Therapeutics (NASDAQ:CADL)

Stephens reaffirmed an "overweight" rating and set a $15.00 price target on shares of Candel Therapeutics in a research note on Monday...

Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the company, MarketBeat...

<ul class="summary-bullets"><li>Traders await the September Core PCE report, the Fed’s preferred inflation gauge. Market odds still overwhelmingly point to a rate cut next week.</li><li>Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.</li><li>Retail chatter is driving sharp moves in names like SMX, SoFi, Rubrik, and Praxis.</li></ul>U.S. stock futures are trading modestly higher in early trade on Friday, suggesting a positive start for Wall Street. It follows a mixed session yesterday and is primarily driven by stronger anticipation of a Federal Reserve rate cut at the upcoming December FOMC meeting.Among crucial economic data to monitor, the&nbsp;September Core PCE Price Index data releases today, which is considered the Fed's preferred inflation gauge.&nbsp;According to the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">&nbsp;CME FedWatch tool</a>, the market is now pricing in an 87% chance of an interest rate cut next Wednesday, down from 90% a day earlier.As of 2:45 a.m. ET on Thursday, the Nasdaq 100 futures and S&amp;P 500 futures were up 0.4% and 0.2%, while the Dow futures and the Russell 2000 futures were flattish with a positive bias. On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and that toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, remained ‘bearish’ early Thursday.&nbsp;Stocks On Trending Watchlist&nbsp;Netflix (NFLX) is reportedly winning the bidding war for a major WBD deal, outbidding Paramount (PSKY). Keep an eye on Warner Bros.Discovery (WBD) stock as well.&nbsp;Security Matters (SMX) is the top-trending stock on Stocktwits as retail chatter rises over a potential short squeeze. Retail sentiment is trending in ‘extremely high’ territory. In other news, the company approved key proposals and re-elected directors at its annual general meeting in Dublin.SoFi Technologies (SOFI) slipped&nbsp;over 6% in after-hours trading after an equity offering. It is looking to raise $1.5 billion in a share sale as it diversifies beyond lending into other products.Apple (AAPL)&nbsp;remains on retail radar on news of executive transitions focused on AI and ongoing regulatory reviews of its App Store rules in Europe.Rubrik (RBRK) saw a significant after-hours pop after a surprise profit and stronger guidance tied to AI demand.Samsara (IOT)&nbsp;has gained retail traction post a strong Q3 earnings print.&nbsp;Wells Fargo raised the firm's price target to $52 from $50 and keeps an Overweight rating on the shares, while JPMorgan raised the firm's price target to $48 from $46 and keeps a Neutral rating.Candel Therapeutics (CADL) is on retail radar on Friday. The company is scheduled to hold&nbsp;an R&amp;D event at 11:00 am ET to detail the BLA roadmap for prostate cancer drug CAN-2409.Praxis Precision Medicines (PRAX)&nbsp;is also inching higher on Stocktwit’s trending list after positive results from the EMBOLD relutrigine study. The company also&nbsp;confirmed it has an upcoming meeting with the FDA to discuss the results and the path forward for a New Drug Application (NDA).&nbsp;Other stocks to keep on the watchlist post their earnings release in after-hours are&nbsp;Domo (DOMO), HP Enterprise (HPE), SentinelOne (S), and DocuSign (DOCU).Key Catalysts To Watch Out ForOn the economic front, investors will be watching for data on inflation and consumer health ahead of the Federal Reserve's final policy meeting of the year.<ul><li>September Core PCE Price Index (10:00 am ET)</li><li>September Personal Income/Spending Data (10:00 am ET)</li><li>December Michigan Consumer Sentiment (10:00 am ET)</li><li>Consumer Credit Change (3:00 pm ET)</li></ul>And on the earnings front, investors will be watching for Victoria’s Secret ($VSCO) pre-market, among others.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar

Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.

Equity

Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.


Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $24.00

Citigroup reduced their price target on shares of Candel Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a research report on Friday...

Candel Therapeutics (NASDAQ:CADL) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen downgraded shares of Candel Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Candel Therapeutics (NASDAQ:CADL) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Candel Therapeutics (NASDAQ:CADL - Get Free Report) posted its earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of...

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are presently covering the stock, Marketbeat.com...

Candel Therapeutics (CADL) on Tuesday said that it has entered into a five-year, $130 million term loan facility with Trinity Capital (TRIN).The loan facility <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/14/3166168/0/en/Candel-Therapeutics-Enters-into-130-Million-Term-Loan-Facility-with-Trinity-Capital-Inc.html">comprises</a> four tranches. While the first tranche of $50 million will be drawn upon closing of the agreement, the second and third tranche totaling $50 million will be available to draw on the achievement of certain milestones, and the fourth tranche of $30 million will be available at the lender’s discretion, the company said. The loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.Proceeds from the loan will be used to refinance certain loan and security agreements, as working capital, and to fund general corporate purposes. The company also said it intends to use the proceeds towards the initiation of a pivotal phase 3 clinical trial of its lead candidate CAN-2409 in non-small cell lung cancer in the second quarter of 2026.Candel Therapeutics shares traded 7% lower on Tuesday morning. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CADL">CADL stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.Candel CFO Charles Schoch said that the strategic financing, in addition to the company’s cash and cash equivalents of $87.2 million as of September 30, strengthens the company’s balance sheet and is also expected to support the company through CAN-2409’s potential launch in early localized prostate cancer and into commercialization.The company plans to submit an application to the U.S. Food and Drug Administration (FDA) for the approval of CAN-2409 for prostate cancer in the fourth quarter of 2026.CADL stock is down by 31% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer 

The company said that the loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CADL News

CADLCandel Therapeutics Inc